Published in World J Gastroenterol on June 28, 2008
Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy. World J Gastroenterol (2011) 0.99
Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma. PLoS One (2013) 0.84
The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma. PLoS One (2013) 0.82
Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer (2011) 0.81
Combined total gastrectomy, total esophagectomy, and D2 lymph node dissection with transverse colonic interposition for adenocarcinoma of the gastroesophageal junction. Surg Today (2011) 0.80
Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients? World J Gastroenterol (2016) 0.80
At the crossroads in the management of gastroesophageal junction carcinomas-where do we go from here? Gastrointest Cancer Res (2008) 0.80
Role of stenting in the palliation of gastroesophageal junction cancer: A brief review. World J Gastrointest Surg (2014) 0.80
Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy. J Gastrointest Oncol (2014) 0.79
Diagnostic value of preoperative CT scan to stratify colon cancer for neoadjuvant therapy. Int J Colorectal Dis (2015) 0.76
Neoadjuvant vs. adjuvant treatment of Siewert type II gastroesophageal junction cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. J Gastrointest Oncol (2016) 0.75
Association of HOTAIR expression with PI3K/Akt pathway activation in adenocarcinoma of esophagogastric junction. Open Med (Wars) (2016) 0.75
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med (2006) 26.37
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med (2008) 12.97
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med (2007) 12.62
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med (1996) 9.85
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol (2006) 9.16
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet (2002) 8.46
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med (1998) 7.60
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys (2000) 7.50
Extended lymph-node dissection for gastric cancer. N Engl J Med (1999) 7.43
Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol (2006) 7.21
Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer (1999) 6.76
Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol (2004) 6.47
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer (1994) 6.31
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol (2001) 6.07
Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg (1998) 4.86
Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol (2004) 4.31
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol (2011) 4.22
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol (2007) 4.03
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol (2004) 2.83
Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol (2006) 2.42
Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg (1999) 2.00
The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet (1994) 1.92
Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol (2003) 1.84
Postoperative chemoradiotherapy for gastric cancer. Ann Oncol (2003) 1.73
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol (2004) 1.64
Optimal locoregional treatment in gastric cancer. J Clin Oncol (2005) 1.54
Biologic predictors of survival in node-negative gastric cancer. Ann Surg (2003) 1.37
Application of minimally invasive treatment for early gastric cancer. J Surg Oncol (2004) 1.37
Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res (1997) 1.27
Preoperative staging of gastric cancer by endoscopic ultrasound: the prognostic usefulness of ascites detected by endoscopic ultrasound. J Clin Gastroenterol (2002) 1.15
Endoscopic resection of early oesophageal cancer. Gut (2007) 1.15
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer (2005) 1.12
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer (2008) 1.10
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 1.08
Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol (2007) 1.04
Principles of surgical treatment for curable gastric cancer. J Clin Oncol (2003) 1.03
Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw (2006) 1.00
Endoscopic ultrasonography. Endoscopy (2002) 0.99
Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer (1999) 0.95
Staging laparoscopy in gastric cancer. Eur J Med Res (2005) 0.90
Neoadjuvant therapy for oesophagogastric cancer. Br J Surg (2004) 0.90
(Neo)adjuvant strategies of advanced gastric carcinoma: time for a change? Dig Dis (2004) 0.84
Minilaparoscopy in the diagnosis of peritoneal tumor spread: prospective controlled comparison with computed tomography. Surg Endosc (2004) 0.83
[New chemotherapeutic options in advanced gastric cancer]. Onkologie (2003) 0.80
The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. Ann Oncol (2006) 0.80
Future strategies and adjuvant treatment of gastric cancer. Ann Oncol (2003) 0.79
Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer. Oncology (Williston Park) (1999) 0.77
Neoadjuvant therapy for upper gastrointestinal tract cancers. Curr Opin Oncol (1996) 0.77
Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg (2012) 19.78
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol (2009) 5.57
ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis. World J Surg (2014) 3.60
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol (2013) 3.53
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol (2012) 2.97
Right-liver living donor transplantation for decompensated end-stage liver disease. Liver Transpl (2002) 2.86
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Gastric Cancer (2013) 2.05
Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res (2005) 2.05
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02
Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int (2008) 1.95
The White test: a new dye test for intraoperative detection of bile leakage during major liver resection. Arch Surg (2008) 1.86
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer (2005) 1.73
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol (2007) 1.71
Genetics of hepatocellular carcinoma. World J Gastroenterol (2007) 1.64
High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol (2009) 1.62
Oncological outcome after local excision of rectal carcinomas. Ann Surg Oncol (2008) 1.47
Minimally invasive versus open esophagectomy: meta-analysis of outcomes. Dig Dis Sci (2010) 1.35
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer (2012) 1.32
Right living donor liver transplantation: an option for adult patients: single institution experience with 74 patients. Ann Surg (2003) 1.31
Achalasia: will genetic studies provide insights? Hum Genet (2010) 1.30
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst (2013) 1.28
Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation (2002) 1.27
Living donor liver transplantation for hepatocellular carcinoma: a single-center preliminary report. Liver Transpl (2006) 1.20
Comparison between minimally invasive video-assisted thyroidectomy and conventional thyroidectomy: is there any evidence-based information? Thyroid (2008) 1.19
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res (2009) 1.18
Visceral artery aneurysms: Incidence, management, and outcome analysis in a tertiary care center over one decade. Eur Radiol (2015) 1.16
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol (2012) 1.16
IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res (2009) 1.09
Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes. Am Surg (2011) 1.07
Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review. World J Gastroenterol (2013) 1.05
PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy. Oncol Rep (2008) 1.04
Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach? Dig Dis Sci (2008) 1.03
The role of surgery in Caroli's disease. J Am Coll Surg (2006) 1.03
Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol Rep (2006) 1.02
Experience after the evaluation of 700 potential donors for living donor liver transplantation in a single center. Liver Transpl (2004) 1.02
Topography of the extrinsic internal anal sphincter nerve supply during laparoscopic-assisted TAMIS TME: five key zones of risk from the surgeons' view. Int J Colorectal Dis (2014) 1.02
Intraoperative application of "white test" to reduce postoperative bile leak after major liver resection: results of a prospective cohort study in 137 patients. Langenbecks Arch Surg (2008) 1.00
Liver transplantation for hepatocellular carcinoma in cirrhosis within the Eurotransplant area: an additional option with "livers that nobody wants". Transplantation (2005) 0.99
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol (2008) 0.99
High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer (2013) 0.99
Liver transplantation for hepatocellular carcinoma: University Hospital Essen experience and metaanalysis of prognostic factors. J Am Coll Surg (2007) 0.99
Orthotopic liver transplantation: T-tube or not T-tube? Systematic review and meta-analysis of results. Transplantation (2009) 0.98
Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev Gastroenterol Hepatol (2011) 0.98
VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J Gastroenterol (2008) 0.98
Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol (2009) 0.97
The use of self-expanding stents in esophageal and gastroesophageal junction cancer palliation: a meta-analysis and meta-regression analysis of outcomes. Dig Dis Sci (2010) 0.97
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer (2011) 0.97
Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int (2008) 0.97
Diagnosis and treatment of pancreatic metastases of a papillary thyroid carcinoma. Thyroid (2010) 0.97
Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? Transplantation (2005) 0.96
Laparoscopic versus open mesh repair for recurrent inguinal hernia: a meta-analysis of outcomes. Am J Surg (2010) 0.96
Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. BMC Cancer (2006) 0.96
Detection of lymph node metastases in esophageal cancer. Expert Rev Anticancer Ther (2011) 0.95
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer (2006) 0.95
Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int (2009) 0.95
Endoscopic findings in patients with Schatzki rings: evidence for an association with eosinophilic esophagitis. World J Gastroenterol (2012) 0.95
Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World J Gastroenterol (2008) 0.92
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol (2009) 0.92
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer (2012) 0.91
Surgical treatment of pancreatic metastases of renal cell carcinoma. JOP (2005) 0.90
Cholangiocellular carcinoma--the role of caudate lobe resection and mesohepatectomy. HPB (Oxford) (2008) 0.89
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma. Virchows Arch (2007) 0.89
International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer (2014) 0.89
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol (2009) 0.89
Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1. Int J Cancer (2012) 0.89
Biliary reconstruction following right adult living donor liver transplantation end-to-end or end-to-side duct-to-duct anastomosis. Langenbecks Arch Surg (2002) 0.88
Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol Rep (2008) 0.88
Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy? World J Gastroenterol (2007) 0.88
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy. Int J Colorectal Dis (2012) 0.88
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. Int J Cancer (2010) 0.87
GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia (2007) 0.87
Salvage plasmapheresis for small-for-size syndrome following hepatic resection for colorectal liver metastases. Int J Colorectal Dis (2007) 0.87
Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int (2014) 0.87
Milan criteria, up-to-seven criteria, and the illusion of a rescue package for patients with liver cancer. Lancet Oncol (2009) 0.86
Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference? J Gastrointest Surg (2008) 0.86
Total mesorectal excision with intraoperative assessment of internal anal sphincter innervation provides new insights into neurogenic incontinence. J Am Coll Surg (2012) 0.86
Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. J Cancer Res Clin Oncol (2013) 0.86